A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
The purpose of this study is in Part 1, to determine the safety of nivolumab, bempegaldesleukin (BEMPEG: NKTR-214), and Tyrosine Kinase Inhibitor (TKI) combination.
Renal Cell Carcinoma
BIOLOGICAL: Nivolumab|DRUG: Axitinib|DRUG: Cabozantinib
Incidence of adverse events (AEs) by severity (Part 1), Up to 2.5 years|Incidence of serious adverse events (SAEs) (Part 1), Up to 2.5 years|Incidence of dose-limiting toxicities (DLTs) (Part 1), Up to 2.5 years|Incidence of AEs leading to discontinuation (Part 1), Up to 5 years|Incidence of immune-mediated adverse events (imAEs) (Part 1), Up to 5 years|Incidence of changes in clinical laboratory results by severity: Hematology tests (Part 1), Up to 2.5 years|Incidence of changes in clinical laboratory results by severity: Clinical Chemistry tests (Part 1), Up to 2.5 years|Incidence of changes in clinical laboratory results by severity: Urinalysis tests (Part 1), Up to 2.5 years
The purpose of this study is in Part 1, to determine the safety of nivolumab, bempegaldesleukin (BEMPEG: NKTR-214), and Tyrosine Kinase Inhibitor (TKI) combination.